We recently published a list of 10 Stocks Drop The Most Amid Investor Caution. In this article, we are going to take a look ...

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.

Summit Therapeutics shares are dropping Monday morning as it reported a fourth-quarter adjusted loss nearly double that of ...

Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good morning and welcome to Summit Therapeutics Fourth Quarter ...

Summit's Co-CEOs, Bob Duggan and Dr. Maky Zanganeh, expressed optimism about the collaboration's ability to accelerate the ...

Discover insights from Summit Therapeutics' Q4 2024 earnings call, highlighting the Pfizer collaboration, ivonescimab trial expansions, and strong ...

Summit Therapeutics (SMMT) announced a clinical trial collaboration with Pfizer (PFE) to evaluate ivonescimab, an investigational PD-1 / VEGF ...

Piotr Swat / SOPA Images / LightRocket via Getty Images Summit Therapeutics shares dropped 14% Monday as it reported a fourth-quarter adjusted loss nearly double that of the previous year.

Summit Therapeutics shares fell after the company reported a wider loss in the fourth quarter. Shares were trading 14% lower at $19.11. The biopharmaceutical oncology company reported a loss of $61.2 ...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 ...

Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.

Summit Therapeutics, Inc. shares rebounded in after-hours trading on Monday after a 14% selloff during regular hours, with ...